LabConnect Expands
LabConnect LLC, a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA.
LabConnect LLC (Seattle, Washington, USA), a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA. The new space will significantly increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to better serve its clients.
Following the completion of phase one of its expansion LabConnect will proceed with stages two and three, which include the addition of more offices and project management space, and building out the PBMC laboratory capabilities.
“We have grown every year since our founding in 2002, and we are committed to maintaining our facilities with cuttingâedge technology,” said Eric Hayashi, president and CEO of LabConnect. “It is an exciting time to be building our business, constantly improving sample testing services to meet clients’ needs, and helping to save lives while supporting clinical trials.”
The expansion is scheduled to be complete in September 2018. For more information, please visit www.labconnectllc.com
Emerging Trends and Challenges in Detecting Residues and Contaminants in Food in the Exposome Era
June 18th 2025This article describes the analytical challenges of chemical exposomics in food safety. The need for high-throughput, multi-platform approaches—such as LC–HRMS and GC–HRMS with IMS—to capture the full spectrum of potential contaminants in our food supply is emphasised.
New Research Explores Role of Nucleotide Hydrophobicity in Oligonucleotide Separation
June 18th 2025Researchers from Waters and Biospring studied the contribution of nucleotide type and modifications on the retention and resolution of 22–24 nt long oligonucleotides in different chromatographic methods.
A Life Measured in Peaks: Honoring Alan George Marshall (1944–2025)
June 18th 2025A pioneer of FT-ICR Mass Spectrometry, Alan G. Marshall (1944–2025), is best known for co-inventing Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS), a transformative technique that enabled ultrahigh-resolution analysis of complex mixtures. Over a career spanning more than five decades at institutions like the University of British Columbia, The Ohio State University, and Florida State University, he published over 650 peer-reviewed papers and mentored more than 150 scientists. Marshall’s work profoundly impacted fields ranging from astrobiology to petroleomics and earned him numerous prestigious awards and fellowships. Revered for his intellect, mentorship, and dedication to science, he leaves behind a legacy that continues to shape modern mass spectrometry.
